GLPwatch
Papers (10404)
Page 95 of 174, ranked by citation count.
- Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.
- Effects of <i>PPARD</i> gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus.
- Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review.
- Drug treatment of obesity.
- Which incretin-based therapy for type 2 diabetes?
- Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice.
- The Use of Decomposition Methods in Real-World Treatment Benefits Evaluation for Patients with Type 2 Diabetes Initiating Different Injectable Therapies: Findings from the INITIATOR Study.
- Mesolimbic exendin-4 attenuates reward salience evoked by neuropeptide Y and ghrelin.
- Patient factors associated with glucagonlike peptide 1 receptor agonist use with and without insulin.
- Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.
- Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.
- Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies.
- Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study.
- Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
- Insulin and IGF-1 receptor autocrine loops are not required for Exendin-4 induced changes to pancreatic β-cell bioenergetic parameters and metabolism in BRIN-BD11 cells.
- Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.
- Lipidized Prolactin-Releasing Peptide Agonist Attenuates Hypothermia-Induced Tau Hyperphosphorylation in Neurons.
- Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting.
- GLP-1 agonists for people living with HIV and obesity, is there a potential?
- Tolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect.
- Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
- Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
- Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.
- Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.
- Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?
- Semaglutide enhances PINK1/Parkin‑dependent mitophagy in hypoxia/reoxygenation‑induced cardiomyocyte injury.
- Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.
- Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates.
- Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data.
- The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial.
- The effects of liraglutide on both hypereosinophilic insulin allergy and the characteristics of anti-insulin antibodies in type 2 diabetes mellitus: a case report.
- Tirzepatide as an Insulin Sensitizer.
- Advancements in the management of obesity: a review of current evidence and emerging therapies.
- Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis.
- Semaglutide or Placebo for Nonalcoholic Steatohepatitis.
- Central nervous system pathways targeted by amylin in the regulation of food intake.
- Liraglutide promotes angiogenesis in adipose tissue via suppression of adipocyte-derived IL-6.
- Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [<sup>68</sup>Ga]Ga-NODAGA-Exendin-4 Produced by a Fully Automated Method.
- Physiologically based pharmacokinetic modelling of semaglutide in children and adolescents with healthy and obese body weights.
- Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.
- Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis.
- Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States.
- GLP-1 provoked severe hypoglycemia in an individual with type 2 diabetes and a benign insulinoma.
- What the diabetologist needs to know about the risk of non-arteritic anterior ischaemic optic neuropathy and GLP-1 receptor agonist use in patients with type 2 diabetes.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials.
- Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
- Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity.
- GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial.
- Tirzepatide-associated starvation ketoacidosis.
- Neurotensin secretion after Roux-en-Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty.
- The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight/obesity: An umbrella review of systematic reviews and meta-analyses.
- Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide.
- Cardiometabolic risk factors efficacy of semaglutide in the STEP program.
- Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study.
- Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System.
- Differential protective effects of exenatide, an agonist of GLP-1 receptor and Piragliatin, a glucokinase activator in beta cell response to streptozotocin-induced and endoplasmic reticulum stresses.
- Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.
- Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
- Noninvasive evaluation of donor and native pancreases following simultaneous pancreas-kidney transplantation using positron emission tomography/computed tomography.
- Lipidized PrRP Analog Exhibits Strong Anti-Obesity and Antidiabetic Properties in Old WKY Rats with Obesity and Glucose Intolerance.